Clinical characteristics of multiple myeloma DLI responders who had antibody response to BCMA
Patient no. . | Patient age at BMT/sex . | Donor age/sex . | Conditioning regimen . | Disease at BMT . | Acute GVHD after BMT, grade . | Chronic GVHD after BMT . | Response after BMT . | Acute GVHD after DLI, grade . | Chronic GVHD after DLI . | Response after DLI . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 51/M | 60/F | CTX/TBI | PR | 0 | - | PR | 1 | Yes, EXT | CR |
| 2 | 37/M | 46/F | CTX/TBI | PR | 0 | - | Relapse | 0 | Yes, EXT | CR |
Patient no. . | Patient age at BMT/sex . | Donor age/sex . | Conditioning regimen . | Disease at BMT . | Acute GVHD after BMT, grade . | Chronic GVHD after BMT . | Response after BMT . | Acute GVHD after DLI, grade . | Chronic GVHD after DLI . | Response after DLI . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 51/M | 60/F | CTX/TBI | PR | 0 | - | PR | 1 | Yes, EXT | CR |
| 2 | 37/M | 46/F | CTX/TBI | PR | 0 | - | Relapse | 0 | Yes, EXT | CR |
CTX indicates cyclophosphamide; TBI, total body irradiation; PR, partial response; -, none; CR, complete response; EXT, extensive.